Status:
COMPLETED
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
Lead Sponsor:
University of Pecs
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
3-18 years
Phase:
EARLY_PHASE1
Brief Summary
The aim of our study is to compare the immune function of patient treated with DMARD (methotrexate), or tumor necrosis factor (TNF)-alpha inhibitor (adalimumab) to healthy children. The study consists...
Eligibility Criteria
Inclusion
- JIA (oligoarticular, polyarticular) treated with MTX or MTX/adalimumab
- Healthy controls
Exclusion
- Children with infection
- Children with active JIA disease
- JIA other than oligoarticular, polyarticular type
Key Trial Info
Start Date :
October 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03833271
Start Date
October 28 2018
End Date
September 30 2019
Last Update
June 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pécs, Medical School, Department of Paediatrics
Pécs, Hungary